Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.
image source: pexels
The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy
The team at the Infectious Diseases Institute, Kampala
DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.
RT @UNITAID: Excluding pregnant women from clinical trials can leave them more vulnerable. To show that such trials are not only needed, but can also be done, @UNITAID funded a trial of a new #HIV treatment specifically in pregnant women. Learn more in @POLITICOEurope: https://t.co/IztKFbXXxF
RT @CatrionaWaitt: European HIV Clinical Forum 2021: a mix of plenaries from the experts, interactive Q&A and debate. Aimed at optimising HIV management in Europe, will also be of interest to global colleagues and registration is FREE FOR HEALTHCARE WORKERS. Don't miss out!